<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181114041652N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-05-26</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of cream containing Green Tea Extract with Pedophilin solution in the treatment of Genital Warts in Women</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of cream containing Green Tea Extract with Pedophilin solution in the treatment of Genital Warts in Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/35222</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: In the visits to follow up by the researcher, the measurements were made and the rate of reduction was lower than the initial size in percent and in each patient there were unwanted inflammatory reactions such as burning, itching, erythema, pain and erosion, as well as the severity of it during the course in the relevant form Registered by the researcher. In the absence of a complication, the score of zero, if there was a mild degree of any complication of score 1, in the mean intensity of score 2, and in case of severity of the 3rd, was attributed to each individual event. Patients treated by the researcher in three The scale is graded according to the percentage of reduction in lesions in terms of size and number indicating recovery rates. More than 91% (complete recovery), between 62 and 91% (moderate improvement), less than 62% (mild recovery), Randomization description: To randomize, we use the blocking method 4 with blocks of constant volume of 4 in two groups A and B.If there are two therapies, there will be six different
 blocks for the four blocks:
1)TTCC 2) TCTC 3) TCCT
4) CCTT 5) CTCT 6) CTTC
We create random numbers between 0 and 600 with computer help. For numbers between 0 and 100/6(TTCC), we count the numbers between 100/6 200/6 (TCTC) and ... and continue this until we reach the desired sample size, Blinding description: In this study, considering that the drug is a control group of the solution and the intervention group is cream, so there is no possibility of blinding the research units, also as the control group is prescribed by the researcher, there is no possibility of blinding for the researcher, so only the possibility of blind data analysis There is.</study_design>
      <phase>3</phase>
      <hc_freetext>Genital warts.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: After the clinical diagnosis of lesions, in the intervention group, 10%  cream of the green tea extract is performed three times a day for 12 weeks or until complete clearance. The cream is used by the patient at home and the patients are followed up by a researcher by phone one weekly and will be visited every two weeks to check lesions. standardization (Determine the amount of Dry Extract Powder) was performed based on Epigallocatechin. Formulation of topical preparation of green tea extract based on oil cream in water containing 19% Sinecatechin (7% Epigallocatechin). The components of the cream include dry extract of green tea, distilled water, glycerin, tween 89, cetyl alcohol, liquid paraffin and oeserin. Finally, a 10% cream containing green tea extract was prepared in 15 g tubes. The cream is used three times a day for 12 weeks or until complete clearance. Intervention 2: In Control group Pedophilin solution 10% is used once a week by the researcher for the patient up to 6 weeks or until complete clearance. In this study, pedophilein solution was prepared by the pharmacist's advisor at the Faculty of Medicine's Laboratory and administered as 10% solution once a week by The researcher will be used for the patient until complete clearance. To prevent damage to the healthy tissue of the skin, around the lesions، vaseline cream is used. 4 to 6 hours after application, the skin should be washed.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is there is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Seyede Zohreh Mousavi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>faculty of Nursing and Midwifery, Ebnesina Ave.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9913197319</zip>
        <telephone>+98 51 3869 1511</telephone>
        <email>mousavizh962@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nahid Golmakani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Factuly of Nursing and Midwifery, Ebnesina Ave.</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9913197319</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>GolmakaniN@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Have written consent to participate in the research, Iranians living in Neyshabur or Mashhad, Age from 18 to 50 years, have literacy to read and write, Do not pregnant and breastfeed,His wife has no other wife, No previous marriage history, There is no specific drug use his, Patient with immunodeficiency disease, There is no history of skin sensitization and skin diseases, Do not smoke,    No other STI infections are present,  Her husband does not have genital warts,Use condoms during treatment, The number of lesions is between 2 and 30 lesions, The level of waste is between 12 and 600 mm cubic meters, Genital warts are limited to the skin
Her husband does not have genital warts
اصلاح شد</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>It is susceptible to prescription. The patient does not want to continue to participate in the research،Pregnant during study,        If it does not use more than 20% of the drug per week</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>B07</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anogenital (venereal) warts A63.0</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: After the clinical diagnosis of lesions, in the intervention group, 10%  cream of the green tea extract is performed three times a day for 12 weeks or until complete clearance. The cream is used by the patient at home and the patients are followed up by a researcher by phone one weekly and will be visited every two weeks to check lesions. standardization (Determine the amount of Dry Extract Powder) was performed based on Epigallocatechin. Formulation of topical preparation of green tea extract based on oil cream in water containing 19% Sinecatechin (7% Epigallocatechin). The components of the cream include dry extract of green tea, distilled water, glycerin, tween 89, cetyl alcohol, liquid paraffin and oeserin. Finally, a 10% cream containing green tea extract was prepared in 15 g tubes. The cream is used three times a day for 12 weeks or until complete clearance.</i_keyword>
      <i_keyword>In Control group Pedophilin solution 10% is used once a week by the researcher for the patient up to 6 weeks or until complete clearance. In this study, pedophilein solution was prepared by the pharmacist's advisor at the Faculty of Medicine's Laboratory and administered as 10% solution once a week by The researcher will be used for the patient until complete clearance. To prevent damage to the healthy tissue of the skin, around the lesions، vaseline cream is used. 4 to 6 hours after application, the skin should be washed</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Percentage recovery of genital warts. Timepoint: At weeks 2, 4, 6, 8, 10, 12 after starting treatment. Method of measurement: The percentage of reduction in lesions is graded according to the dimensions and number indicating the rate of recovery of the lesions. More than 90% (complete recovery), between 65% and 90% (moderate improvement), less than 65% (mild recovery).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-10</approval_date>
        <contact_name>Ethics committee of Mashhad of Medical Science</contact_name>
        <contact_address>Quraishi Building، University Street، Mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
